Christopher Sweeney, MBBS, professor of medicine, Harvard Medical School, and physician, Dana-Farber Cancer Institute, discusses the treatment-related adverse events associated with adding enzalutamide or non-steroidal anti-androgens to testosterone suppression treatment and docetaxel in patients with metastatic hormone-sensitive prostate cancer, as seen in the ENZAMET trial.<br />
Christopher Sweeney, MBBS, professor of medicine, Harvard Medical School, and physician, Dana-Farber Cancer Institute, discusses the treatment-related adverse events (TRAEs) associated with adding enzalutamide (Xtandi) or non-steroidal anti-androgens to testosterone suppression treatment and docetaxel in patients with metastatic hormone-sensitive prostate cancer, as seen in the ENZAMET (ANZUP 1304) trial (NCT02446405).
Patients in the study were randomized 1:1 to receive either testosterone suppression plus enzalutamide or the non-steroidal anti-androgens, bicalutamide (Casodex), nilutamide (Nilandron), or flutamide (Eulexin). The phase III study results show that TRAEs occurred more frequently in the patients who received enzalutamide versus the non-steroidal anti-androgen, said Sweeney.
All TRAEs were between grades 1 and 3, with fatigue being the most common. Patients also experienced hypertension, syncope, seizures, and falls. Investigators noticed that adding enzalutamide to docetaxel also increased the rate of adverse events often seen with docetaxel alone. These AEs included neutropenic fever, sensory neuropathy, eye tearing, and nail discoloration. Sweeney says that it’s important to counsel patients about the possibility of increased docetaxel-related symptoms when adding enzalutamide to their treatment.
Behind the FDA Approval of Liso-cel for Relapsed/Refractory CLL/SLL
March 15th 2024In an interview with Targeted Oncology, Tanya Siddiqi, MD, discussed the rationale behind the TRANSCEND CLL 004 study supporting the FDA approval of lisocabtagene maraleucel in chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More
First Real-World Data on Second-Generation AR Inhibitor Use in nmCRPC
September 18th 2023A review of real-world data from the DEAR study of darolutamide, enzalutamide and apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer is given by Alicia Morgans, MD, MPH.
Listen